Full Title
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients (A062102) (CIRB)Purpose
Idecabtagene vicleucel is a form of CAR T immunotherapy for multiple myeloma. People who have this treatment are usually monitored (watched) afterward, with no additional myeloma medications. In this study, researchers want to see if giving iberdomide as maintenance therapy after idecabtagene vicleucel is better than monitoring.
Iberdomide activates immune cells called T cells, which could make idecabtagene vicleucel work better. Iberdomide may keep multiple myeloma under control longer than with the usual approach of monitoring after idecabtagene vicleucel. It may also help people with multiple myeloma live longer.
If you join this study, you will be randomly assigned to take iberdomide or just be monitored after idecabtagene vicleucel therapy. Iberdomide is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have received idecabtagene vicleucel for multiple myeloma within 80 to 110 days of entering the study.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please contact Dr. Hamza Hashmi’s office at 646-608-4348.